Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 13/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 10/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.40 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843851 | 0.91 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL6652484 | 0.82 | CHRNA7 (0.59) | CHRNA7CHRNB2CHRNA4HTR3ANPC1 | |
| SCHEMBL6632433 | 0.82 | CHRNA7 (0.59) | CHRNA7CHRNB2CHRNA4HTR3ANPC1 | |
| SCHEMBL5917962 | 0.82 | CHRNA7 (0.59) | CHRNA7CHRNB2CHRNA4HTR3ANPC1 | |
| Hydrochloric Acid SCHEMBL6478770 | 0.81 | CHRNA7 (0.58) | CHRNA7CHRNB2CHRNA4HTR3ANPC1 | |
| Hydrochloric Acid SCHEMBL6633801 | 0.81 | CHRNA7 (0.58) | CHRNA7CHRNB2CHRNA4HTR3ANPC1 | |
| SCHEMBL6659231 | 0.80 | CHRNA7 (0.42) | CHRNA7CHRNB2CHRNA4HTR3ANPC1 | |
| SCHEMBL6636628 | 0.80 | CHRNA7 (0.63) | CHRNA7NPC1RAB9A | |
| SCHEMBL5917953 | 0.79 | DRD4 (0.51) | NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL6099824 | 0.78 | DRD4 (0.50) | CHRNA7NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828330-B2 | Central nervous system disorders; schizophrenia; psychological disorders | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | claimed |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | claimed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | claimed |
| US-6828330-B2 | Central nervous system disorders; schizophrenia; psychological disorders | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | disclosed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | CHRNA7 672/4885CHRNB2 1367/4885CHRNA4 999/4885 |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | CHRNA7 672/4885CHRNB2 1367/4885CHRNA4 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.